Literature DB >> 19624361

Risk factors for perioperative adverse events in children with myotonic dystrophy.

Joanna L Sinclair1, Peter W Reed.   

Abstract

BACKGROUND: This study was conducted to identify patient-related, surgical, and anesthetic factors that would help predict adverse events and allow for better planning of perioperative care in children with myotonic dystrophy.
METHODS: This is a retrospective chart review from a large tertiary pediatric hospital. Data were collected on demographics, disease severity, surgical procedure, and anesthetic technique. Perioperative adverse events were recorded.
RESULTS: Records on 27 patients having 78 anesthetics over a 17.5-year period were reviewed. The overall frequency of postoperative respiratory complications was 10%. Significant risk factors were high muscular impairment rating scale (MIRS) grade (P = 0.007), at least 2300 cytosine, thymine, guanine (CTG) repeats on the protein kinase gene of chromosome 19q (P = 0.009), a longer duration of surgery (RR = 14.0 for surgery lasting at least 1 h; P = 0.002), perioperative morphine use (RR = 7.7, 95% CI 2.2-12.8; P = 0.005), intubation (P = 0.02), and the use of muscle relaxant without reversal (RR = 15.5, P = 0.0002). Using a multivariate risk model, only MIRS grade and the use of muscle relaxant without reversal were shown to be significant independent risk factors (RR = 24.9, P < 0.0001).
CONCLUSIONS: The MIRS is a statistically significant and clinically useful tool for predicting high perioperative risk. Patients with a high MIRS grade should therefore be considered for postoperative intensive care. The use of muscle relaxant without reversal was also shown to be a significant risk factor. Patients who require morphine infusions postoperatively might also be most safely managed in a high dependency unit.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19624361     DOI: 10.1111/j.1460-9592.2009.03079.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  8 in total

1.  Associations between polysomnography measurements and postoperative adverse respiratory events in children with neuromuscular disease.

Authors:  Haley Fishman; Jemila S Hamid; Nick Barrowman; Franco Momoli; Ian Maclusky; Sherri Lynne Katz
Journal:  J Clin Sleep Med       Date:  2021-04-01       Impact factor: 4.062

2.  Desflurane anaesthesia in myotonic dystrophy.

Authors:  Ranju Gandhi; Anil Kumar Jain; Jayashree Sood
Journal:  Indian J Anaesth       Date:  2011-01

3.  Sensitivity to rocuronium-induced neuromuscular block and reversibility with sugammadex in a patient with myotonic dystrophy.

Authors:  Akihiro Kashiwai; Takahiro Suzuki; Setsuro Ogawa
Journal:  Case Rep Anesthesiol       Date:  2012-04-09

4.  Undiagnosed myopathy before surgery and safe anaesthesia table.

Authors:  Carlo P Trevisan; Alma Accorsi; Lucia O Morandi; Tiziana Mongini; Gennaro Savoia; Elvira Gravino; Corrado Angelini; Vincenzo Tegazzin
Journal:  Acta Myol       Date:  2013-10

5.  Opioid use may be associated with postoperative complications in myotonic dystrophy type 1 with high-grade muscular impairment.

Authors:  Chan-Sik Kim; Jin-Mo Park; Donghwi Park; Doo-Hwan Kim; Jin-Sung Park
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

Review 6.  Anaesthesia and neuromuscular disorders: what a neurologist needs to know.

Authors:  Heinz Jungbluth; Nicol C Voermans; Luuk R van den Bersselaar; Marc M J Snoeck; Madelief Gubbels; Sheila Riazi; Erik-Jan Kamsteeg
Journal:  Pract Neurol       Date:  2020-10-27

7.  Total intravenous anesthesia in a 10-month-old patient with congenital myotonic dystrophy undergoing endoscopic third ventriculostomy -A case report-.

Authors:  Jung Hwa Joh; Ji Yeon Kim; Seung-Hye Baek; Jun-Gol Song; Yu Mi Lee; Joung Uk Kim
Journal:  Korean J Anesthesiol       Date:  2012-08-14

8.  Orthopaedic Disorders in Myotonic Dystrophy Type 1: descriptive clinical study of 21 patients.

Authors:  Lisa Schilling; Raimund Forst; Jürgen Forst; Albert Fujak
Journal:  BMC Musculoskelet Disord       Date:  2013-12-01       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.